Australia's most trusted
source of pharma news
Tuesday, 21 July 2026
Posted 20 July 2026 AM
Last week the TGA approved a raft of generics targeting PBS listed drugs, sponsored by six companies.
Among the list is Sandoz’s Tofacitinib Sandoz, marking the second copycat of Pfizer’s JAK inhibitor Xeljanz to be registered in Australia, following Accelagen’s generic brands (Tofadoz, Tofacitinib Lupin, and MSN Tofacitinib) which were approved last month.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.